BioCentury | Mar 6, 2021
Product Development

The pace of new modality approvals is picking up

Last week’s FDA approval of Sarepta’s Amondys 45 marks the ninth new modality drug to be approved in the last year, a sign that the pace of new therapeutic formats making it to...
BioCentury | Nov 23, 2020
Product Development

Immunocore charts the path for bispecifics in solid tumors with Phase III readout

With a positive Phase III readout in metastatic uveal melanoma, Immunocore has become the first company to solve one of the biggest challenges in immuno-oncology: applying T cell-engaging bispecifics to solid tumors.  The data suggest...
BioCentury | Feb 7, 2020
Product Development

Latest data for Tmunity’s CRISPR-edited T cells support safety, fall short on efficacy

Carl June and colleagues at the University of Pennsylvania reported that the cancers of all three patients treated in a Phase I trial of Tmunity Therapeutics Inc.’s CRISPR-edited NY-ESO TCR T cell therapy had progressed...
BioCentury | Jan 13, 2020
Clinical News

Adaptimmune rises on early promise for SPEAR TCR cell therapies in solid tumors

Cancer cell therapy play Adaptimmune gained $2.66 (200%) to $3.99 on Monday after announcing a new set of data for its SPEAR T cell therapies in four different solid tumor indications. The announcement by Adaptimmune...
BioCentury | Nov 7, 2019
Clinical News

First U.S. clinical CRISPR data give early safety signal for ex vivo editing

CRISPR cleared its earliest safety hurdle with the first clinical data on the gene editing technology in the U.S., but it's still too early to tell whether that safety signal will persist and apply to...
BioCentury | Nov 6, 2019
Financial News

A2 emerges with $57M series A, engineered T cells for solid tumors

A2 debuted Tuesday with a $57 million series A round and two T cell immunotherapy strategies for solid tumors. The Column Group led the tranched round, with participation by Vida Ventures, Samsara BioCapital and Nextech...
BioCentury | Nov 1, 2019
Emerging Company Profile

Tmunity: Manufacturing momentum for CAR and TCR therapies

Tmunity’s $75 million series B round will enable the company to keep advancing its CMC capabilities alongside its clinical and preclinical engineered CAR and TCR therapies for solid and blood tumors. Andreessen Horowitz (a16z) led...
BioCentury | Oct 19, 2019
Product Development

How GSK has rebuilt its oncology pipeline from the ground up

Less than two years into GSK's cancer rebuild, Hal Barron is making measurable strides to reposition the pharma as an immunology-focused company. His turnaround boasts an expanded immuno-oncology pipeline, replete with multiple modalities, and two...
BioCentury | Oct 9, 2019
Company News

GSK partners with Lyell to bring gene, cell therapies into solid tumors

...patients with advanced or recurrent non-small cell lung cancer who are positive for NY-ESO-1- or CTAG2...
...and ex-Juno CEO Hans Bishop, who is now Grail’s CEO. Targets: CTAG2 (LAGE1; NY-ESO-2) - Cancer/testis antigen 2...
BioCentury | Sep 13, 2019
Emerging Company Profile

Valo: adding tumor antigens to oncolytic viruses

With platforms that can rapidly display tumor-specific antigens on oncolytic viruses without genetic engineering, Valo is positioning itself as an attractive collaborator for immuno-oncology companies. Oncolytic viruses kill cancer cells by lysing the cells, and...
Items per page:
1 - 10 of 145